PRTK Paratek Pharmaceuticals Inc

Abbott Cooper PLLC announces that it is investigating Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) (“Paratek” or the “Company”) on behalf of the Company’s investors.

The investigation seeks to determine whether Franchise Group stockholders have been injured due to any violations of fiduciary duty or federal securities law in connection with Paratek’s agreement to be acquired by affiliates of Gurnet Point Capital, LLC and Novo Holdings A/S.

Paratek stockholders are encouraged to contact Abbott Cooper PLLC by calling (475) 333-0674, emailing ac@abbottlawyer.com or visiting our website at www.abbottlawyer.com for additional information about this investigation as well as their legal rights and options.

Abbott Cooper PLLC is dedicated to shareholders’ rights and empowering shareholders through strategic counsel and legal advocacy. For additional information about Abbott Cooper PLLC, please visit www.abbottlawyer.com.

Attorney advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230809631795/en/

Abbott Cooper PLLC J. Abbott R. Cooper, Esq. (475) 333-0674 www.abbottlawyer.com

Paratek Pharmaceuticals (NASDAQ:PRTK)
Gráfica de Acción Histórica
De Ene 2025 a Feb 2025

Paratek Pharmaceuticals (NASDAQ:PRTK)
Gráfica de Acción Histórica
De Feb 2024 a Feb 2025